A Phase 2, Multicenter, Double-Blind, Randomized, Parallel Group, 4-Week Inpatient Study To Evaluate The Safety And Efficacy Of Two Fixed Doses Of PF-02545920 Compared To Placebo In The Treatment Of Acute Exacerbation Of Schizophrenia Using Risperidone As An Active Control.

Trial Profile

A Phase 2, Multicenter, Double-Blind, Randomized, Parallel Group, 4-Week Inpatient Study To Evaluate The Safety And Efficacy Of Two Fixed Doses Of PF-02545920 Compared To Placebo In The Treatment Of Acute Exacerbation Of Schizophrenia Using Risperidone As An Active Control.

Completed
Phase of Trial: Phase II

Latest Information Update: 12 Apr 2013

At a glance

  • Drugs Mardepodect (Primary) ; Risperidone
  • Indications Schizophrenia
  • Focus Adverse reactions; Biomarker; Pharmacogenomic; Pharmacokinetics; Therapeutic Use
  • Most Recent Events

    • 10 Apr 2012 Actual patient number is 259 according to ClinicalTrials.gov.
    • 10 Apr 2012 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 02 Apr 2012 New source identified and integrated (European Clinical Trials Database, EudraCT2010-020764-38).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top